Patents by Inventor Klaus Peter Bogeso
Klaus Peter Bogeso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7772240Abstract: A compound 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpiperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.Type: GrantFiled: August 18, 2004Date of Patent: August 10, 2010Assignee: H. Lundbeck A/SInventors: Benny Bang-Andersen, Klaus Peter Bogeso, Henrik Svane, Lars Ole Lyngso, Allan Carsten Dahl, Mark Howells, Klaus Gjervig Jensen, Tomas Mow
-
Publication number: 20090176808Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.Type: ApplicationFiled: March 18, 2009Publication date: July 9, 2009Applicant: H. Lundbeck A/SInventors: Thomas Ivo Franciscus Hubert Cremers, Hakan Vilhelm Wikstrom, Johan Antonie Den Boer, Fokko Jan Bosker, Bernard Hendrik Cornelis Westerink, Klaus Peter Bogeso, Sandra Hogg, Arne Mork
-
Publication number: 20080119547Abstract: The present invention relates to aminoindane derivatives having the formula I wherein X, Y, U, R1-2, and R13-16 are as defined in the claims, or an acid addition salt thereof. The compounds of the invention posses the combined effect of serotonin reuptake inhibition and norepinephrine uptake inhibition.Type: ApplicationFiled: January 9, 2008Publication date: May 22, 2008Applicant: H. Lundbeck A/SInventors: Klaus Peter Bogeso, Ask Puschl, Jan Kehler
-
Patent number: 7351734Abstract: The present invention relates to aminoindane derivatives having the formula I wherein X, Y, U, R1-2, R13-16 and R are as defined in the claims, or an acid addition salt thereof. The compounds of the invention posses the combined effect of serotonin reuptake inhibition and norepinephrine uptake inhibition.Type: GrantFiled: December 18, 2002Date of Patent: April 1, 2008Assignee: H. Lundbeck A/SInventors: Klaus Peter Bøgesø, Ask Püschl, Jan Kehler, Peter Bregnedal
-
Patent number: 6921774Abstract: The invention provides novel compounds of the formula I below: wherein the meaning of each substituent is defined in the application. The compounds are useful as inhibitors of the glycine transporter and useful in the treatment of diseases responsive to the inhibition of the glycine transporter. The invention provides a pharmaceutical composition comprising a compound of Formula I as defined above and the use of compounds as above for the manufacture of medicaments for treatment of diseases responsive to ligands of the glycine transporter.Type: GrantFiled: January 17, 2003Date of Patent: July 26, 2005Assignee: H. Lundbeck A/SInventors: Ejner Knud Moltzen, Paul Garrick Smith, Christian Krog-Jensen, Klaus Peter Bøgesø
-
Publication number: 20040167210Abstract: The present invention relates to the crystalline base of the well known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of citalopram, such as the hydrobromide, using the base, the salts obtained by said process and formulations containing such salts.Type: ApplicationFiled: December 30, 2003Publication date: August 26, 2004Inventors: Hans Petersen, Klaus Peter Bogeso, Per Holm
-
Publication number: 20040132808Abstract: The present invention relates to the crystalline base of the well known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of citalopram, such as the hydrobromide, using the base, the salts obtained by said process and formulations containing such salts.Type: ApplicationFiled: December 19, 2003Publication date: July 8, 2004Inventors: Hans Petersen, Klaus Peter Bogeso, Per Holm
-
Publication number: 20030181445Abstract: The invention provides novel compounds of the formula I below: 1Type: ApplicationFiled: January 17, 2003Publication date: September 25, 2003Applicant: H. Lundbeck A/SInventors: Ejner Knud Moltzen, Garrick Paul Smith, Christian Krog-Jensen, Klaus Peter Bogeso
-
Publication number: 20030078442Abstract: The present invention relates to the crystalline base of the well known antidepressant drug citalopram,1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of citalopram, such as the hydrobromide, using the base, the salts obtained by said process and formulations containing such salts.Type: ApplicationFiled: September 12, 2002Publication date: April 24, 2003Applicant: H. Lundbeck A/SInventors: Hans Petersen, Klaus Peter Bogeso, Per Holm
-
Publication number: 20030032636Abstract: The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic activity for the treatment of depression and other affective disorders. The combined serotonin reuptake inhibiting effect and the 5-HT2C antagonistic, partial agonistic or inverse agonistic effect may reside within the same chemical compound or in two different chemical compounds.Type: ApplicationFiled: June 6, 2002Publication date: February 13, 2003Applicant: H. Lundbeck A/SInventors: Thomas Ivo Franciscus Hubert Cremers, Hakan Vilhelm Wikstrom, Johan Antonie Den Boer, Fokko Jan Bosker, Bernard Hendrik Cornelis Westerink, Klaus Peter Bogeso, Sandra Hogg, Arne Mork
-
Patent number: 6492374Abstract: The present invention relates to benzofuran derivatives having general Formula (I) wherein A is selected from (1), (2), (3), (4) wherein Z is O or S; s is 0 or 1; q is 0 or 1; R4 is hydrogen, C1-6-alkyl, C2-6-alkenyl, C26-alkynyl, C1-6-alkyl-aryl, or C1-6-alkyl-O-aryl; D is a spacer group selected from branched or straight chain C1-6-alkylene, C2-6-alkenylene and C2-6-alkynylene; its enantiomers, and pharmaceutically acceptable acid addition salt thereof. The compounds are potently binding to the 5-HT1A receptor.Type: GrantFiled: June 4, 2001Date of Patent: December 10, 2002Assignee: H. Lundbeck A/SInventors: Kim Andersen, Mario Rottländer, Klaus Peter Bøgesø, Henrik Pedersen, Thomas Ruhland, Robert Dancer
-
Publication number: 20020103249Abstract: The present invention relates to the use of a combination of irindalone and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.Type: ApplicationFiled: December 6, 2000Publication date: August 1, 2002Applicant: H. Lundbeck A/SInventors: Klaus Peter Bogeso, Thomas Ivo Franciscus Hubert Cremers
-
Publication number: 20020032205Abstract: The present invention relates to benzofuran derivatives having general Formula (I) 1Type: ApplicationFiled: June 4, 2001Publication date: March 14, 2002Applicant: H. Lundbeck A/SInventors: Kim Andersen, Mario Rottlander, Klaus Peter Bogeso, Henrik Pedersen, Thomas Ruhland, Robert Dancer
-
Publication number: 20010031784Abstract: The crystalline base of the compound citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, having the formula 1Type: ApplicationFiled: December 5, 2000Publication date: October 18, 2001Inventors: Hans Petersen, Klaus Peter Bogeso, Per Holm
-
Patent number: 6291689Abstract: A method for the preparation of citalopram is described comprising reduction of the oxo group of a compound of formula (IV), wherein R1 is CN, C1-6 alkyloxycarbonyl or C1-6 alkylaminocarbonyl, ring closure of the resulting hydroxy compound thereby obtaining the corresponding 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran, then if R1 is cyano using it directly in the next step and if R1 is C1-6 alkyloxycarbonyl or C1-6 alkylaminocarbonyl, conversion of the compound to the corresponding compound wherein R1 is a cyano; and alkylation of the resulting 5-cyano compound with 3-dimethyl-aminopropylhalogenide in basic conditions thereby obtaining citalopram.Type: GrantFiled: May 3, 2000Date of Patent: September 18, 2001Assignee: H. Lundbeck A/SInventors: Hans Petersen, Klaus Peter Bøgesø, Michael Bech Sommer
-
Patent number: 6258842Abstract: A method for the preparation of citalopram is described comprising reaction of a compound of Formula (IV) wherein R1 is H or C1-6alkylcarbonyl successively with a Grignard reagent of 4-halogen-fluorophenyl and a Grignard reagent of 3-halogen-N,N-dimethylpropylamine, effecting ring closure of the resulting compound of Formula (IV) and converting the resulting 1,3-dihydroisobenzofuran compound to the corresponding 5-cyano derivative, i.e. citalopram.Type: GrantFiled: April 28, 2000Date of Patent: July 10, 2001Assignee: H. Lundbeck, A/SInventors: Hans Petersen, Peter Bregnedal, Klaus Peter Bogeso
-
Patent number: 6200999Abstract: (3-Alkoxyisoxazol-4-yl)-substituted 2-amino carboxylic acid derivatives and sulfur analogues thereof having general formula (I) or (II), wherein R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalk(en)yl, cycloalk(en)yl-alk(en/yn)yl or optionally substituted phenyl-alk(en/yn)yl; A is a bond or a hydrocarbon spacer group; B is a group —CRa(NRbRc)—COOR5 wherein Ra-Rc are independently hydrogen or alkyl, and R5 is defined as R1 or pivaloyloxymethyl, or B is a group of Formula (III), wherein R2, R3 and R4 are independently selected from hydrogen, a non-aromatic hydrocarbon group, phenyl- and thienyl-alkyl, and a hetero aliphatic group, or R3 and R4 are connected, thereby forming an alkylene, alkenylene or alkynylene group, or R4 and R2 are connected in order to form an alkylene, alkenylene or alkynylene group, optionally substituted with hydroxy or methyl, or to form CH2—O—CH2; E is COOR6, where R6 is defined as R5, or E is a tetrazolyl or triazolyl; X is OType: GrantFiled: May 20, 1999Date of Patent: March 13, 2001Assignee: H. Lundbeck A/SInventors: Benny Bang-Andersen, Klaus Peter Bøgesø, Povl Krogsgaard-Larsen, Sibylle Moltzen Lenz
-
Patent number: RE36374Abstract: The present invention relates to novel compounds of the following formula, where the dotted line designates in optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,4- or 1,3,4-oxadiazole,R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifuoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy;R.sup.2 and R.sup.Type: GrantFiled: May 13, 1996Date of Patent: November 2, 1999Assignee: H. Lundbeck, A/SInventors: Klaus Peter Bogeso, Klaus Gundertofte, Ejner Knud Moltzen, Henrik Pedersen